We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to interferon-alfa plus cytarabine (IFN þ AraC). BCR-ABL/BCR% levels were measured by real-time quantitative RT-PCR and were significantly lower for the imatinib-treated patients at all time points up to 18 months, Po0.0001. The median levels for imatinib-treated patients continued to decrease and had not reached a plateau by 24 months. A total of 24 IFN þ AraC-treated patients crossed over to imatinib. Once imatinib commenced, the median BCR-ABL/BCR% levels in these patients were not significantly different to those on first-line imatinib for the equivalent number of months. The incidence of progression in imatinib-treated patients, defined by hematologic, cytogenetic or quantitative PCR criteria, was significantly higher in the patients who failed to achieve a 1 log reduction by 3 months or a 2 log reduction by 6 months, P ¼ 0.002. A total of 49 patients were screened for BCR-ABL kinase domain mutations. Mutations were detected in two imatinib-treated patients who crossed over from IFN þ AraC and both lost their imatinib response. In conclusion, first-line imatinib-treated patients had profound reductions in BCR-ABL/BCR%, which significantly exceeded those of IFN þ AraC-treated patients and early measurements were predictive of subsequent response.
Introduction
The Philadelphia chromosome (Ph) is characteristic of chronic myeloid leukemia (CML) and results in the fusion of sequences from the BCR and ABL genes. The BCR-ABL protein is an activated tyrosine kinase that is causally associated with CML. [1] [2] [3] [4] The efficacy and safety of the tyrosine kinase inhibitor imatinib mesylate (Glivec, Novartis Pharmaceuticals, Basel, Switzerland) has been demonstrated in a number of trials involving patients in all phases of the disease, and the best responses are observed in patients in the chronic phase of CML. [5] [6] [7] [8] [9] A phase 3 study (the IRIS trial) comparing first-line imatinib therapy with conventional therapy comprising interferon alfa plus cytarabine (IFN þ AraC) for newly diagnosed chronic-phase patients has recently been reported. 8 At the time of the study design, IFN þ AraC was considered the most effective treatment for newly diagnosed patients who were not eligible for allogeneic transplant. 10 The study demonstrated that imatinib was superior to IFN þ AraC as first-line therapy as assessed by cytogenetic response rates and freedom from disease progression. The estimated rate of complete cytogenetic response (CCyR, defined as no Ph-positive metaphases) at 18 months was 76% for imatinib-treated patients and 14.5% for IFN þ AraC-treated patients. 8 Real-time quantitative PCR (RQ-PCR) techniques have become a standard for the molecular monitoring of minimal residual disease in hematologic malignancies. 11 Since the majority of newly diagnosed patients treated with imatinib achieve a CCyR, molecular monitoring of residual disease by quantitation of BCR-ABL mRNA is required to further stratify treatment response and to detect early loss of response. Hughes and colleagues reported the molecular responses as measured by RQ-PCR in patients treated in the phase 3 study once a CCyR was achieved. 11 After 12 months of treatment, BCR-ABL levels had fallen by at least 3 logs in 57% of patients who had achieved a CCyR. This level of reduction at 12 months of imatinib therapy was associated with 100% progression-free survival over the subsequent 12 months. This compared to 95% for patients in a CCyR with a less than 3 log reduction and 85% in patients not in a CCyR (Po0.001). A 43 log reduction of BCR-ABL was termed a major molecular response (MMR). 12 Our laboratory was one of the three laboratories participating in molecular response assessment in these study patients who achieved CCyR. 12 That molecular study did not examine the BCR-ABL levels in patients who failed to achieve a CCyR nor did it report the molecular response of the many patients who crossed over to imatinib after IFN þ AraC failure.
As a supplement to the IRIS trial molecular study, 12 we investigated the molecular response in greater detail in a subset of 55 patients from Australia and New Zealand who were enrolled in the phase 3 study. The assessments of BCR-ABL levels in peripheral blood were performed at regular defined time points independent of their cytogenetic response. Our substudy provides a direct comparison of the molecular response of the two treatment regimes in a cohort of newly diagnosed patients and was not restricted to patients achieving a CCyR. We continued to assess patients who crossed over to imatinib early in the disease after IFN þ AraC failure and compared their molecular response to those treated with firstline imatinib. Mutational analysis of the BCR-ABL kinase domain was performed in the first-and second-line imatinibtreated patients who had received imatinib therapy for up to 30 months. This was to evaluate the incidence of this mechanism of imatinib resistance in early chronic-phase patients. Mutations in the BCR-ABL kinase domain are highly associated with acquired imatinib resistance in patients in blast crisis, accelerated phase and late chronic phase (412 months since diagnosis). [13] [14] [15] [16] The prognostic significance of early BCR-ABL measurements in the imatinib-treated patients was examined in terms of subsequent molecular and cytogenetic response.
Patients and methods

Patients and samples
The institutional ethics committees of all centers approved the study and all patients provided written informed consent. A total of 62 newly diagnosed patients with chronic-phase CML from Australia and New Zealand were enrolled in the phase 3 study. Details on study design, conduct and treatment plan were previously reported. 8 Dose adjustments were allowed according to the study protocol and patients were able to cross over to the alternative treatment arm if they met stringently applied criteria. 8 Progression was defined by any of the following events, death from any cause during treatment, the development of accelerated phase or blast crisis, loss of complete hematologic response or loss of a major cytogenetic response (MCyR, 0-35% Ph-positive metaphases). 8 For the purpose of this study, we also included an increase in the BCR-ABL/BCR% value of greater than 10-fold by RQ-PCR or the appearance of additional cytogenetic abnormalities in the Ph-positive clone as an indication of progression.
A total of 31 patients were randomized to each arm, but four withdrew from the study by 3 months of therapy (two were randomized to imatinib and two to IFN þ AraC). Of the remaining 58 patients, 55 had 20 ml of peripheral blood collected for molecular analysis at more than 1 time point and were included in the study. A total of 28 patients commenced treatment with imatinib and 27 with IFN þ AraC. The patient baseline characteristics as determined immediately prior to commencing study therapy were not significantly different to the total group of patients enrolled in the phase 3 study, 8 except for the prestudy platelet count in the IFN þ AraC patients (P ¼ 0.02). In our substudy, no patient crossed over to IFN þ AraC from imatinib, but 24 IFN þ AraC-treated patients crossed over to imatinib. In the majority of cases, patients had samples collected prior to commencing study therapy and at 3, 6, 9, 12, 18 and 24 months. A subset of nine patients at one center had samples collected monthly for the first 6 months of study and 3 monthly thereafter. In addition, 12 patients had simultaneous bone marrow aspirates collected for RQ-PCR. After 24 months, the molecular assessments were continued at 3-month intervals and 40 patients have had additional samples collected. The median time from study entry to when the last molecular analysis was performed was 30 months (range 6-33). In total, 90% of the scheduled samples were collected and 495 RNA samples were analyzed.
RNA extraction, cDNA synthesis and quantitative PCR
To minimize RNA degradation, samples were processed into Trizol RNA stabilization solution (Invitrogen Life Technologies, Carlsbad, CA, USA) at the site laboratory at a median of 2.5 h (range 1-23 h) after collection and stored at À801C. Samples were sent frozen to the testing laboratory in Adelaide where RNA was extracted according to the manufacturer's instructions. Superscript II reverse transcriptase (Invitrogen Life Technologies) was used for cDNA synthesis using 1 mg of total RNA. 17 We used RQ-PCR with TaqMan fluorescent hybridization probes and the ABI Prism 7700 Sequence Detection System (Applied Biosystems Foster City, CA, USA) to quantitate the level of BCR-ABL transcripts. 17 The transcript level of normal BCR was quantitated to control for variations in the quality of the RNA, and to control for differences in the efficiency of the reverse-transcription reaction. A very low BCR level indicated unacceptable RNA quality as previously described, 17, 18 with 4.5% of samples being rejected as poor quality. The results were reported as a ratio of BCR-ABL/BCR%. The logarithmic decline of BCR-ABL/BCR% from a standardized baseline rather than the absolute value was used in the IRIS molecular trial to enable comparison between the three participating reference laboratories. 12 In this substudy, we also determined the reduction of BCR-ABL/BCR% from the standardized baseline as previously described. 12 Briefly, this baseline was derived from a pool of samples collected from study patients just prior to starting the study drug. The same samples were tested at the three reference laboratories. The median BCR-ABL/BCR% value was determined by each laboratory and this was designated the standardized baseline value for that laboratory. The standardized baseline value in our laboratory was 80%. This value was not significantly different to the prestudy value of the 55 patients included in the substudy (71%).
We defined a MMR as a 43 log reduction of BCR-ABL/BCR% from the standardized baseline. 12 A CCyR was defined as 0% Ph-positive metaphases and a partial cytogenetic response (PCyR) was defined as 1-35% Ph-positive metaphases.
BCR-ABL kinase domain mutation analysis
Mutation analysis was performed using a seminested direct sequencing technique of the complete BCR-ABL kinase domain. 14, 16 This technique permitted the detection of single or multiple mutations in patients with disease status ranging from CCyR to overt relapse at a sensitivity of 20%. The sensitivity was determined by diluting a BCR-ABL-positive cell line containing the Y253F mutation with wild-type BCR-ABL-positive cells from 10 to 90% in 10% increments. The BCR-ABL mutant was clearly detected at a dilution ratio of 20%.
Statistical analysis
The Mann-Whitney U test was used to compare the BCR-ABL levels between the groups and some parameters of the patient baseline characteristics. The w 2 statistic was used to determine the association between the 6-month BCR-ABL level and disease outcome in imatinib-treated patients, and some parameters of the patient baseline characteristics. Kaplan-Meier curves were constructed to estimate the probability of achieving at least a 3 log reduction in BCR-ABL levels and compared using the logrank test. The Spearman rank correlation coefficient was used to assess the correlation between simultaneous peripheral blood and bone marrow BCR-ABL levels.
Results
Treatment response
The median follow up of the 28 imatinib-treated patients was 30 months (range 6-33 months) from the start of first-line therapy. Of the 28 patients, 22 (79%) achieved and maintained a CCyR.
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Of the remaining six patients, four had progression (one developed accelerated phase, one developed additional chromosomal abnormalities in the Ph-positive clone (both discontinued the study) and two had a 410-fold increase in BCR-ABL/ BCR%). The two patients with progression evaluated by quantitative PCR received an increased imatinib dose and both regained disease control. Of the 27 IFN þ AraC-treated patients, only two achieved a CCyR (7.4%). Two patients came off study due to disease progression to accelerated phase and blast crisis and one patient withdrew consent at 12 months. The remaining 24 patients crossed over to imatinib from 3.5 to 22 months (median 11.5 months) of study. A total of 10 of these patients were intolerant of IFN þ AraC and six were reluctant to continue treatment using the defined protocol criteria, 8 two had cytogenetic resistance, three had hematologic resistance and three lost their hematologic response. The median duration from diagnosis to the commencement of second-line imatinib was 16 months (range 6-26 months).
The median follow up of second-line imatinib therapy in the 24 crossover patients was 17 months (range 6-28 months). Of the 24 patients, 18 (75%) achieved and maintained a CCyR. The median month when CCyR was achieved after the start of second-line imatinib was 6 months (range 3-17 months). This was no different to the first-line imatinib-treated patients (median 6 months, range 3-15 months). Of the remaining six patients, two had progression (one had a 410-fold increase in the BCR-ABL/BCR% and the appearance of additional chromosomal abnormalities in the Ph-positive clone, and one had a loss of a complete hematologic response with an 8.4-fold increase in BCR-ABL/BCR%).
Comparison of molecular response to first-line therapy
The BCR-ABL/BCR% values of the patients treated with first-line imatinib were compared to patients treated with first-line IFN þ AraC at each time point. The median values were significantly lower in the imatinib-treated patients compared to the IFN þ AraC-treated patients at each time point up to 18 months (Table 1 and Figure 1 ). However, only five patients remained on IFN þ AraC at 18 months.
In imatinib-treated patients, there was a rapid decrease in the BCR-ABL/BCR% level within the first 3 months, with a median 1.6 log reduction from the standardized baseline. All patients who achieved at least a 1 log reduction at 3 months achieved a CCyR by 9 months of imatinib treatment. Only one of the five patients with less than 1 log reduction at 3 months subsequently achieved a CCyR. The median values continued to decrease and had not reached a plateau by 24 months of imatinib therapy, at which time there was a median 3.5 log reduction from the standardized baseline. The number of patients achieving an MMR increased at every time point. At 12 and 24 months, 50 and 72%, respectively, had achieved a 43 log reduction in BCR-ABL/BCR% ( Table 1 ). The effect of imatinib was durable. A total of 17 patients with an MMR were tested beyond 24 months (median 30 months, range 27-33) and all have ongoing MMR. At 24 months of imatinib therapy, two patients had undetectable BCR-ABL transcripts (undetectable for the first time at 6 and 24 months, and both patients had sustained undetectable levels for 26 and 6 months of follow-up, respectively). This represents 7% of the substudy patients treated with first-line imatinib.
For IFN þ AraC-treated patients, a decrease in the median BCR-ABL/BCR% value also occurred within the first 3 months (0.4 log). However, the decrease in these patients was at least 1 log less than for imatinib-treated patients at 3 months, and by 12 months was over 2 logs less ( Table 1) .
Comparison of molecular response of first-line imatinib to second-line imatinib after crossover from IFN þ AraC In general, the 24 patients who crossed over to imatinib had achieved a reduction of the leukemic load while on IFN þ AraC since the median BCR-ABL/BCR% value precrossover was significantly lower (0.5 logs) than the standardized baseline value ( Table 2 ). The BCR-ABL/BCR% values of the crossover patients were compared to the values of the first-line imatinibtreated patients at the equivalent number of months on imatinib therapy. The difference in the median values between the two groups at the equivalent time point on imatinib therapy was not significant (Table 2 ). To date, two crossover patients have attained an undetectable BCR-ABL level, which was first achieved after 12 and 21 months of imatinib and this has been maintained for 6 and 3 months, respectively. Figure 1 illustrates the difference between the median BCR-ABL/BCR% values at each sampling time point between the two groups. One of the patients who crossed over to imatinib developed additional chromosomal abnormalities in the Ph-positive clone, which was preceded by a 10-fold increase in the BCR-ABL/BCR% level. The increase corresponded with the detection of a BCR-ABL kinase domain mutation. The molecular response of this patient is shown in Figure 2a , as is the response of another crossover patient who continued to have reducing levels of BCR-ABL/ BCR% up to 21 months of imatinib and a sustained CCyR (Figure 2b ).
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Figure 1
Median log reduction of BCR-ABL. The median log reduction of BCR-ABL/BCR% are plotted for the patients treated with first-line imatinib, first-line IFN þ AraC and second-line imatinib after crossover. The vertical bars are the 25th-75th percentile values. There was a significantly superior molecular response in patients treated with first-line imatinib compared to those treated with first-line IFN þ AraC at each treatment time point (Po0.0001). Similarly, patients who crossed over to imatinib after IFN þ AraC failure had significant reductions in BCR-ABL/BCR% levels, which were not statistically different to the median levels achieved in first-line imatinib-treated patients after similar periods of imatinib therapy. Prognostic significance of the 3 and 6 month BCR-ABL value in imatinib-treated patients in terms of subsequent achievement of a major molecular response
Responses in imatinib-
treated patients compared to IFN þ AraC-treated patients S Branford et al
SPOTLIGHT
The achievement of a 43 log reduction in BCR-ABL/BCR% levels is associated with a very low incidence of progression. 12 . We examined the 3 and 6 month levels to determine if patients who do not achieve this level of reduction by 24 months of imatinib can be identified at an earlier time point in their
Figure 2
Individual molecular responses of four patients illustrating the variable patterns observed. The broken line on the y-axis indicates that BCR-ABL was not detected below that point. Patients (a) and (b) were treated with first-line IFN þ AraC and both crossed over to imatinib, patient (a) due to hematologic resistance and patient (b) due to intolerance. The shaded areas represent the time on IFN þ AraC before crossover. Patient (a) achieved a CCyR only after the imatinib dose was increased to 600 mg. The subsequent significant increase in BCR-ABL/BCR% at 22 months of imatinib corresponded with the detection of the F359V mutation. In contrast, patient (b) had a rapid reduction in BCR-ABL/BCR% level after crossover that continued to decrease. Patients (c) and (d) were treated with first-line imatinib and by 6 months the BCR-ABL/BCR% level in both patients was 42 logs below the standardized baseline. Patient (c) was the only patient of those who had reductions of 42 logs at 6 months who subsequently lost response. The BCR-ABL/BCR% level of patient (d) continued to decrease while that of patient (c) increased significantly indicating relapse.
Figure 3
BCR-ABL/BCR% values grouped according to their cytogenetic response category at the time of molecular analysis. There was a significant difference between the median values of each group (Po0.0001). The dark shading indicates the results that were 42 logs below the standardized baseline and were categorized as CCyR. The lighter shading indicates the values categorized as a PCyR and were 41 log below the standardized baseline. A 41 log reduction is the molecular equivalent of an MCyR since 97.3% of values categorized as MCyR by cytogenetic analysis were below this level.
Responses in imatinib-treated patients compared to IFN þ AraC-treated patients S Branford et al treatment. In all, 28 first-line imatinib-treated patients, six patients with at least 24 months of second-line imatinib therapy and one who had ceased second-line imatinib therapy at 12 months due to cytogenetic resistance were evaluated. At 3 months, the patients were divided into those with a 42 log reduction in BCR-ABL/BCR% (n ¼ 12) and those with 0-2 log reduction (n ¼ 23). Kaplan-Meier analysis demonstrated that an estimated 100% of patients with a 42 log reduction at 3 months will achieve an MMR by 24 months, whereas an estimated 54.2% of patients with a 0-2 log reduction achieved these levels by 24 months, Figure 4a . Of the 35 patients, 31 had not achieved at least a 3 log reduction by 6 months and these patients were divided by their 6 month BCR-ABL/BCR% value as those with a 42 log reduction (n ¼ 22) and those with 0-2 log reduction (n ¼ 9), to estimate their chance of achieving a subsequent 3 log reduction. Kaplan-Meier analysis demonstrated that an estimated 86.4% of patients with a 42 log reduction at 6 months will achieve an MMR by 24 months. None of the nine patients with a 0-2 log reduction achieved these levels, Figure 4b . Therefore, these data suggest that the 3 month BCR-ABL/BCR% value can identify a group of patients who will subsequently achieve significant reductions and have a low risk of progression. The 6 month BCR-ABL/BCR% value can identify patients who may never achieve these significant reductions and therefore are at a higher risk of subsequent progression.
Prognostic significance of the 6 month BCR-ABL value in imatinib-treated patients in terms of subsequent progression
To determine if subsequent progression could be predicted early in therapy, we examined the 6 month BCR-ABL/BCR% values. We separated patients according to their 6 month value using a 2 log reduction from the standardized baseline value as the dividing point. In total, 28 first-line imatinib-treated patients, six patients with at least 24 months of second-line imatinib therapy and one who had ceased second-line imatinib therapy at 12 months due to cytogenetic resistance were evaluated. A total of 26 patients had a 42 log reduction at 6 months and nine had 0-2 log reduction. In the subsequent 18 months of imatinib therapy, only one of the 26 patients (3.8%) with 42 log reduction had a significant increase in the BCR-ABL/BCR% value of more than 10-fold. No BCR-ABL kinase domain mutation was detected at the time of increase. The molecular response of this first-line imatinib-treated patient is shown in Figure 2c , as is the response of a patient who continued to have a reduction in BCR-ABL/BCR% on first-line imatinib treatment and a sustained CCyR (Figure 2d) . The BCR-ABL/BCR% levels of the remaining 25 patients stabilized (eight patients), continued to decrease (14 patients) or became undetectable (three patients) by 24 months.
In contrast, of the nine patients with 0-2 log reduction by 6 months, five had progression (56%). This was a significantly higher incidence than that of the patients with 42 log reduction at 6 months (P ¼ 0.002). Of the four patients who did not lose response and had a 6 month value of 0-2 logs, only one subsequently had a reduction of BCR-ABL/BCR% that was 42 logs below the standardized baseline. This patient did not achieve an MMR by 24 months of imatinib. At each subsequent time point after 6 months of imatinib therapy, the median levels were significantly lower in the patients with at least a 2 log reduction by 6 months (Po0.01). Therefore, the 6 month BCR-ABL/BCR% value was highly predictive of subsequent molecular and clinical response.
Mutation analysis of the BCR-ABL kinase domain
In total, 49 imatinib-treated patients were tested for mutations in the BCR-ABL kinase domain (27 first-line and 22 after crossover). Multiple mutation tests were performed and the median number of analyses was 2 per patient. The median duration of imatinib therapy when the last test on each patient was performed was 24 months for first-line patients (range 6-30 months) and 14 months for crossover patients (range 6-28 months).
No mutations were detected in any of the patients treated with first-line imatinib, including the four patients with progression. However, the F359V mutation was detected in a patient who crossed over to imatinib because of hematologic resistance after 6 months of IFN þ AraC (Figure 2a) . The mutation was first detected at 22 months of imatinib therapy at which time there had been a 10-fold increase in the BCR-ABL/BCR% level. The ratio of mutant to wild-type BCR-ABL increased in the subsequent 5 months as the patient had a steady rise in the BCR-ABL level. The patient also had two copies of the Ph on the most recent cytogenetic analysis. The T315I mutation was detected in a second patient who had crossed over to imatinib therapy after 7 months of IFN þ AraC due to intolerance. The mutation was detected at 21 months of second-line imatinib after the BCR-ABL/BCR% value had increased by 8.4-fold and the patient had lost a complete hematologic response. No other patient treated with second-line imatinib had detectable mutations.
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Figure 4
Kaplan-Meier estimate of the probability of achieving a major molecular response by 24 months of imatinib therapy. The patients were analysed according to whether they achieved a 42 log reduction of BCR-ABL/BCR% at (a) 3 months or (b) 6 months. The patients who achieved a 42 log reduction at either time point had a significantly higher probability of achieving a 43 log reduction.
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Comparison of BCR-ABL levels in peripheral blood and bone marrow
Comparison of BCR-ABL/BCR% levels in peripheral blood and bone marrow was performed in 69 matched samples collected at 3-30 months after the start of study. There was no significant difference between the median levels (P ¼ 0.41), and there was a good correlation as indicated by the Spearman correlation coefficient of 0.96. This correlation in imatinib-treated newly diagnosed patients was no different to the correlation observed in 56 matched samples of patients off study measured at our institution. Figure 5 illustrates the correlation between peripheral blood and bone marrow of the combined 125 samples. The median BCR-ABL/BCR% value of peripheral blood was 1.4% and the bone marrow was 1.6% (P ¼ 0.49). There were nine matched samples where BCR-ABL was undetectable in both the blood and the bone marrow and in no case was BCR-ABL detected in one tissue type but not in the other.
Discussion
Our study followed a subset of newly diagnosed patients with CML in chronic phase who were enrolled in the IRIS phase 3 study and were randomized to imatinib or IFN þ AraC. We compared the molecular response at regular treatment time points for all patients, including those who crossed over to imatinib therapy and irrespective of the achievement of a CCyR. We have shown that the median reductions in BCR-ABL/BCR% levels were significantly greater in the first-line imatinib-treated patients compared to the first-line IFN þ AraC-treated patients at each time point up to 18 months of study as measured by RQ-PCR. Beyond that time most IFN þ AraC-treated patients had crossed over to imatinib. The median BCR-ABL/BCR% levels for the imatinib-treated patients decreased at every measurement time point and had not reached a plateau by 24 months of therapy. All patients in our substudy who were treated with firstline IFN þ AraC ceased therapy. Interestingly, those who did not fail IFN þ AraC chose to discontinue therapy and cross over to imatinib when a protocol amendment allowed.
The comparison between first-line and second-line imatinib therapy demonstrated similar substantial reductions in BCR-ABL/BCR% at the equivalent time point on imatinib. The rate of CCyR in this subset of second-line imatinib treated patients at 75% was higher than that reported by O'Brien for the crossover patients in the phase 3 study (40%). 8 Our CCyR rate was calculated in patients who had received a median of 17 months of second-line imatinib therapy, whereas the rate of CCyR reported by O'Brien 8 was based on a median of 11 months of imatinib and the follow up in some patients was short. Our substudy also had a higher number of crossover patients who were intolerant of IFN þ AraC or were reluctant to continue IFN þ AraC therapy compared to the total group of phase 3 crossover patients (67% compared to 51%, respectively). The rate of CCyR in our crossover patients was also higher than that seen in a much larger study of chronic-phase patients treated with 400 mg after IFN failure (41%). 6 However, the median disease duration before commencing imatinib in that study was longer (34 months, range 3-218) than in our group (16 months, range . That study also demonstrated that patients who commenced imatinib after IFN failure early in the disease had a higher rate of MCyR than those who started imatinib later in the course of the disease, and that patients with hematologic resistance to IFN had a low response rate to imatinib. Contributing factors to the high response rate in our subset of crossover patients may be that they commenced imatinib early in the disease, that there was a high proportion who were intolerant rather than resistant to IFN and that the leukemic load was already significantly reduced in most patients at imatinib start.
We have found that the measurement of BCR-ABL at 3 and 6 months was predictive of the subsequent cytogenetic and molecular response in imatinib-treated patients. Previous studies demonstrated similar findings in patients treated with imatinib in accelerated-phase and chronic-phase patients who had failed IFN. [18] [19] [20] The IRIS trial molecular study demonstrated that the achievement of at least a 3 log reduction (MMR) in first-line imatinib-treated patients by 12 months is highly predictive of progression-free survival at 24 months. 12 In our substudy, we found that early BCR-ABL measurements could predict a subsequent MMR. The achievement of a 42 log reduction of BCR-ABL/BCR% by 3 months of imatinib was highly predictive of achieving an MMR by 24 months. However, we found that none of the patients who only had a 0-2 log reduction at 6 months achieved an MMR and only one of these patients subsequently achieved a CCyR. These patients also had the highest incidence of disease progression. The results suggest that the risk of subsequent progression or failure to achieve significant reductions in BCR-ABL can be predicted in some patients quite early by precise quantitative PCR. Therefore, BCR-ABL measurements at 3 and 6 months may identify patients who should be considered for higher imatinib dose, combination therapy or possibly allogeneic transplant.
We found minimal overlap in the BCR-ABL values between the cytogenetic response categories. This finding is in contrast to a recent report that found a considerable overlap in BCR-ABL values between the categories. 21 Our data suggest that precise RQ-PCR techniques using peripheral blood to measure BCR-ABL levels may be used as an accurate marker for response to imatinib therapy. This is particularly important to provide early prognostic information in newly diagnosed patients since the majority achieve a CCyR on imatinib therapy. 8 Increasing BCR-ABL levels have been reported to be predictive of relapse after bone marrow transplant and during IFN therapy. [22] [23] [24] Two of the patients in our study had significant increases after achieving a CCyR. The Ph was subsequently detected in both patients indicating that serial molecular monitoring in imatinib-treated patients may accurately predict progression.
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Figure 5
Correlation between blood and bone marrow. There was a good correlation between the peripheral blood and bone marrow BCR-ABL/BCR% values.
Responses in imatinib-treated patients compared to IFN þ AraC-treated patients S Branford et al While RQ-PCR analysis of BCR-ABL in our study correlated with the cytogenetic response, the technique will not detect cytogenetic abnormalities in the Ph-negative cells. It has been reported that imatinib may favor the manifestation of Phnegative clonal disorders in some patients, [25] [26] [27] particularly in patients previously treated with cytarabine and idarubicin. 25 This phenomenon has not yet been reported in patients treated with first-line imatinib; however, the data suggest that regular cytogenetic analysis should be performed to complement molecular monitoring.
Our substudy data demonstrated in the first-line imatinibtreated patients that the BCR-ABL levels continued to decrease and the number achieving an MMR increased over time. However, the number of patients with sustained undetectable levels of BCR-ABL was low, as has been reported previously. 28 Of the patients in CCyR for at least 18 months, all but two still had detectable levels of BCR-ABL at 24 months of imatinib but the levels were still decreasing in almost half of these patients. This raises the possibility that BCR-ABL may become undetectable in an increasing number of patients over time. Further follow up in these patients may determine if a sustained period where BCR-ABL is undetected will equate to long-term diseasefree survival or even a cure as it frequently does with allogeneic transplant. [29] [30] [31] [32] Of the patients treated with imatinib in our substudy, six had progression as defined by hematologic, cytogenetic or quantitative PCR criteria. BCR-ABL kinase domain sequence analysis in the imatinib-treated patients detected a mutation in two of these patients, both of whom had crossed over from IFN þ AraC to imatinib within 1 year from diagnosis. No mutations were detected in any patient with ongoing imatinib response. This represents a mutation detection rate of only 4% of the 49 patients tested for mutations. This finding was in contrast to our previous survey of an unselected population of late chronicphase patients, where 22% had detectable mutations. 16 The median time between diagnosis and commencing imatinib therapy in our substudy patients was 0.48 years, which was considerably shorter than the group of late chronic-phase patients at a median of 3.5 years. 16 This finding further supports the notion that over time, increasing clonal diversity enhances the probability of developing imatinib-resistant mutations. 15 The significant reduction of BCR-ABL seen in the majority of the imatinib-treated patients in our substudy and the associated inactivation of the BCR-ABL kinase may also make the development of mutations less likely in this cohort. Mutation analysis is an important prognostic investigation since we have found that virtually all patients with detectable mutations develop some degree of loss of response. 16 The F359V mutation detected in one patient confers a 1.8-2.8-fold decrease in sensitivity to imatinib in biochemical and cellular assays, respectively. 33 This suggests that codon 359 plays only a modest role in imatinib binding and resistance may be overcome by dose escalation. The T315I mutation is one of the most resistant mutations in vitro. 13, 15, 34, 35 To our knowledge, this is the first report of the detection of a mutation in patients treated with imatinib therapy in early chronic phase. So far, we have not detected mutations in any first-line imatinibtreated patient nor in any patient who achieved an MMR.
In summary, we report that first-line imatinib-treated chronicphase patients had a significantly superior molecular response compared to those treated with first-line IFN þ AraC. The median BCR-ABL levels of imatinib-treated patients continued to decrease up to 24 months, indicating that the levels may become undetectable in more patients with longer follow up. Patients who crossed over to imatinib early in the disease after IFN þ AraC failure had similar substantial reductions. Similar BCR-ABL levels were found in peripheral blood and the corresponding bone marrow sample demonstrating that peripheral blood monitoring is appropriate for imatinib-treated patients and allows more frequent analysis when indicated. BCR-ABL kinase domain mutation detection in early chronic-phase patients continues to be a rare occurrence compared to the frequency of detection in late chronic-phase patients. The measurement of BCR-ABL at 3 and 6 months is highly predictive of subsequent achievement of significant reductions in molecular levels and identifies patients at an increased risk of progression.
